AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20516633 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg/day for 2 weeks)
Number of subjects: 52
Study 20516633 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 52
Study 20516633 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 52
Study 18612156 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine as second treatment (1,250 mg/m² twice daily, days 1 through 14)
Number of subjects: 40
Study 18612156 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine as first treatment (1,250 mg/m² twice daily, days 1 through 14)
Number of subjects: 40
Study 18612156 — intervention group
Group type: COMPARATOR
Intervention: FU/LV as first treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Number of subjects: 40
Study 18612156 — intervention group
Group type: COMPARATOR
Intervention: FU/LV as second treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Number of subjects: 40
Study 16021114 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotape
Number of subjects: 217
Study 16021114 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinic visit
Number of subjects: 217
Study 11936398 — intervention group
Group type: EXPERIMENTAL
Intervention: External neurolysis of the lingual nerve
Number of subjects: 10
Study 10558962 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 80 microgram
Number of subjects: 108
Study 10558962 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 250 microgram
Number of subjects: 108
Study 10558962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial stapler technique
Number of subjects: 38
Study 8919382 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutured technique
Number of subjects: 38
Study 2060447 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation for 10 weeks
Number of subjects: 18
Study 2060447 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 18
Study 6313458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice a day
Number of subjects: 44
Study 6313458 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 200 mg three times a day and 400 mg at night
Number of subjects: 44
Study 31872869 — intervention group
Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 99
Study 31872869 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 dissection
Number of subjects: 99
Study 30575979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego depletion (experimental group)
Number of subjects: 200
Study 30575979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 29208190 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session, manualised, psychosocial, gender-specific group intervention plus BBV transmission information booklet and treatment as usual (TAU)
Number of subjects: 176
Study 29208190 — intervention group
Group type: COMPARATOR
Intervention: Information booklet plus treatment as usual (TAU)
Number of subjects: 176
Study 29208190 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session, manualised, psychosocial, gender-specific group intervention
Number of subjects: 176
Study 24494935 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 63
Study 24494935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 24494935 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 63
Study 24494935 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC pain subscale
Number of subjects: 63
Study 24494935 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC function scale
Number of subjects: 63
Study 24378255 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 221
Study 24378255 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 221
Study 22565002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d plus Everolimus 10 mg/d
Number of subjects: 111
Study 22565002 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d alone
Number of subjects: 111
Study 21163014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation training
Number of subjects: 59
Study 17469692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (especially donepezil)
Number of subjects: 0
Study 17469692 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA receptor antagonist (memantine)
Number of subjects: 0
Study 17469692 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 16035127 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed bright light therapy (morning or afternoon exposure at > or = 2500 lux)
Number of subjects: 70
Study 16035127 — intervention group
Group type: COMPARATOR
Intervention: Usual indoor light (150-200 lux)
Number of subjects: 70
Study 11831542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/325 mg
Number of subjects: 23
Study 11831542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 7.5 mg/500 mg
Number of subjects: 23
Study 11831542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/650 mg
Number of subjects: 23
Study 11831542 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 10030391 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid diet
Number of subjects: 32
Study 10030391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauric acid diet
Number of subjects: 32
Study 10030391 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 32
Study 10030391 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diets (lauric and palmitic)
Number of subjects: 32
Study 10030391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diets
Number of subjects: 32
Study 7541269 — intervention group
Group type: EXPERIMENTAL
Intervention: CY mobilized PBPC
Number of subjects: 30
Study 2188165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril (SLC) 25 mg
Number of subjects: 40
Study 2188165 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nifedipine (SLN) 10 mg
Number of subjects: 40
Study 6633598 — intervention group
Group type: COMPARATOR
Intervention: Blinded randomization
Number of subjects: 145
Study 6633598 — intervention group
Group type: COMPARATOR
Intervention: Unblinded randomization
Number of subjects: 145
Study 6633598 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized studies
Number of subjects: 145
Study 31253599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 84
Study 31253599 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 84
Study 28917493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial annular velocity (MAV) changes in e'
Number of subjects: 224
Study 28917493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial annular velocity (MAV) changes in s'
Number of subjects: 224
Study 28917493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial annular velocity (MAV) changes in a'
Number of subjects: 224
Study 27624720 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT) post-arthroplasty at 10 weeks
Number of subjects: 380
Study 27624720 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT) post-arthroplasty at 26 weeks
Number of subjects: 380
Study 27624720 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between anchor- and distribution-based methods
Number of subjects: 380
Study 24218432 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine±perindopril
Number of subjects: 1006
Study 24218432 — intervention group
Group type: COMPARATOR
Intervention: Atenolol±bendroflumethiazide
Number of subjects: 1006
Study 18827360 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) formulations of glipizide (fast, moderate, slow)
Number of subjects: 6
Study 18827360 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of glipizide
Number of subjects: 6
Study 15465619 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and referral intervention program initiated by community pharmacists
Number of subjects: 0
Study 15465619 — intervention group
Group type: COMPARATOR
Intervention: Usual care (written asthma information, referral to a respiratory therapist, usual pharmacy and physician care)
Number of subjects: 0
Study 10688396 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 10 mg
Number of subjects: 234
Study 10688396 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 234
Study 10688396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9239453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 30
Study 9239453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 30
Study 9239453 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 30
Study 9239453 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 30
Study 8325622 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg and then 1 mg/4 hr over 24 hr) and transdermal nitroglycerin (10 mg/12 hr over 24 hr)
Number of subjects: 87
Study 8325622 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (continuous intravenous infusion of 25 micrograms/hr over 12 hr and then 100 micrograms at hr 12 and hr 18 subcutaneously)
Number of subjects: 87
Study 3716920 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (children who saw videotaped television programs with drinking)
Number of subjects: 0
Study 3716920 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who saw videotaped television programs without drinking)
Number of subjects: 0
Study 30374950 — intervention group
Group type: EXPERIMENTAL
Intervention: TEDA with bupivacaine (B-group)
Number of subjects: 19
Study 30374950 — intervention group
Group type: COMPARATOR
Intervention: Saline (P-group)
Number of subjects: 19
Study 27807890 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg extended-release aspirin
Number of subjects: 155
Study 27807890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 26681730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1375
Study 26681730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1375
Study 24375476 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic application for 30 minutes
Number of subjects: 4
Study 24375476 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic application for 60 minutes
Number of subjects: 4
Study 24375476 — intervention group
Group type: COMPARATOR
Intervention: Control (no hydration)
Number of subjects: 4
Study 24375476 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic application for 30 minutes vs 60 minutes
Number of subjects: 4
Study 23250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural mouthrinsing with 0.2% chlorhexidine gluconate
Number of subjects: 90
Study 23250175 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume evacuator attachment during ultrasonic scaling
Number of subjects: 90
Study 23250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preprocedural mouthrinsing with 0.2% chlorhexidine gluconate and high volume evacuator attachment
Number of subjects: 90
Study 23250175 — intervention group
Group type: COMPARATOR
Intervention: Control group (ultrasonic scaling without rinsing or suction)
Number of subjects: 90
Study 19846028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 19846028 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0
Study 17236796 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin exposure (5-200 microM)
Number of subjects: 36
Study 17236796 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin exposure (50 microM and above)
Number of subjects: 36
Study 17236796 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin exposure (all concentrations)
Number of subjects: 36
Study 15000501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 34
Study 15000501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg ethanol
Number of subjects: 34
Study 15000501 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 34
Study 11602546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for 3 months)
Number of subjects: 63
Study 11602546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 63
Study 11602546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11602546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 63
Study 9222303 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (serum AFP and real-time ultrasound every 6 months)
Number of subjects: 18820
Study 9222303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 18820
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli (spoken words in male voice)
Number of subjects: 0
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli (written words)
Number of subjects: 0
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli (words spoken in female voice)
Number of subjects: 0
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli (digits shown in one location)
Number of subjects: 0
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli (digits shown in another location)
Number of subjects: 0
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli (sounds)
Number of subjects: 0
Study 7584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli (pictures)
Number of subjects: 0
Study 3038422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril
Number of subjects: 40
Study 3038422 — intervention group
Group type: COMPARATOR
Intervention: Oral captopril
Number of subjects: 40
Study 29620995 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of modified FOLFOX6 (mFOLFOX6)
Number of subjects: 2010
Study 29620995 — intervention group
Group type: COMPARATOR
Intervention: 6 months of modified FOLFOX6 (mFOLFOX6)
Number of subjects: 2010
Study 29620995 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX
Number of subjects: 2010
Study 29620995 — intervention group
Group type: COMPARATOR
Intervention: 6 months of CAPOX
Number of subjects: 2010
Study 29620995 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of mFOLFOX6
Number of subjects: 2010
Study 29620995 — intervention group
Group type: COMPARATOR
Intervention: 6 months of mFOLFOX6
Number of subjects: 2010
Study 29620995 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 in T4 and/or N2 population
Number of subjects: 2010
Study 29620995 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 in T1-3N1 population
Number of subjects: 2010
Study 27617366 — intervention group
Group type: EXPERIMENTAL
Intervention: One of four text versions of a warning label (e.g., SAFETY WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay)
Number of subjects: 2202
Study 27617366 — intervention group
Group type: COMPARATOR
Intervention: No warning label
Number of subjects: 2202
Study 27617366 — intervention group
Group type: EXPERIMENTAL
Intervention: One of four text versions of a warning label
Number of subjects: 2202
Study 24899156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh avocado (23 g of lipid) with high-β-carotene tomato sauce (33.7 mg of β-carotene)
Number of subjects: 12
Study 24899156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh avocado (23 g of lipid) with raw carrots (27.3 mg of β-carotene and 18.7 mg of α-carotene)
Number of subjects: 12
Study 24899156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh avocado (23 g of lipid)
Number of subjects: 12
Study 21721947 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin group (bonded with two-step bonding resin, Optibond FL, and Tetric EvoFlow)
Number of subjects: 52
Study 21721947 — intervention group
Group type: COMPARATOR
Intervention: Nonresin group (bonded without applying Optibond FL)
Number of subjects: 52
Study 21721947 — intervention group
Group type: COMPARATOR
Intervention: Nonresin group
Number of subjects: 52
Study 20840515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Number of subjects: 42
Study 20840515 — intervention group
Group type: COMPARATOR
Intervention: Control (saline of equal volume)
Number of subjects: 42
Study 18022349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable mini-plate fixation
Number of subjects: 40
Study 18022349 — intervention group
Group type: COMPARATOR
Intervention: Titanium mini-plate fixation
Number of subjects: 40
Study 15935646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: CI 10 mL/h, PCEA bolus 6 mL, 8‐min lockout
Number of subjects: 220
Study 15935646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: CI 10 mL/h, PCEA bolus 12 mL, 16‐min lockout
Number of subjects: 220
Study 15935646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: CI 15 mL/h, PCEA bolus 6 mL, 8‐min lockout
Number of subjects: 220
Study 15935646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: CI 15 mL/h, PCEA bolus 12 mL, 16‐min lockout
Number of subjects: 220
Study 15935646 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 220
Study 14646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sediment podocalyxin (u-sed-PCX) measured by ELISA in children with glomerular diseases (group I and II)
Number of subjects: 111
Study 14646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sediment podocalyxin (u-sed-PCX) in group I (inflammatory glomerular diseases)
Number of subjects: 111
Study 14646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of proteinuria with u-sed-PCX in group I
Number of subjects: 111
Study 14646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of u-sed-PCX levels in acute vs chronic phase in group I
Number of subjects: 111
Study 14646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of u-sed-PCX with histological findings in renal biopsies
Number of subjects: 111
Study 14646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high level of u-sed-PCX
Number of subjects: 111
Study 11140343 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement services during the intake period
Number of subjects: 0
Study 11140343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible engagement services provided to women during the intake period
Number of subjects: 0
Study 11140343 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study 8988070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg twice daily)
Number of subjects: 19
Study 8988070 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (30 mg once daily)
Number of subjects: 19
Study 1455272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 1455272 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 1455272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Propofol and Midazolam
Number of subjects: 0
Study 6738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Stutterers
Number of subjects: 14
Study 6738029 — intervention group
Group type: COMPARATOR
Intervention: Nonstutterers (Control)
Number of subjects: 14
Study 29878869 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg salbutamol administered before exercise
Number of subjects: 32
Study 29878869 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with asthma
Number of subjects: 32
Study 29878869 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 27559041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose / 10 mg maintenance dose once daily)
Number of subjects: 50
Study 27559041 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (180 mg loading dose / 90 mg maintenance dose twice daily)
Number of subjects: 50
Study 25344328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg plus standard treatment
Number of subjects: 108
Study 25344328 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo plus standard treatment
Number of subjects: 108
Study 22907057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (HS; 350 mmol day(‐1))
Number of subjects: 12
Study 22907057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) during high-sodium diet
Number of subjects: 12
Study 19876001 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) diet
Number of subjects: 164
Study 19876001 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CARB) diet
Number of subjects: 164
Study 19876001 — intervention group
Group type: COMPARATOR
Intervention: Protein (PROT) diet
Number of subjects: 164
Study 17400660 — intervention group
Group type: EXPERIMENTAL
Intervention: HeO2
Number of subjects: 16
Study 17400660 — intervention group
Group type: COMPARATOR
Intervention: Room Air (RA)
Number of subjects: 16
Study 17400660 — intervention group
Group type: COMPARATOR
Intervention: Mask O2
Number of subjects: 16
Study 17400660 — intervention group
Group type: COMPARATOR
Intervention: Nasal O2
Number of subjects: 16
Study 17400660 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 16
Study 16342925 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 0
Study 16342925 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha treatment
Number of subjects: 0
Study 16342925 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated imatinib treatment (80% favorable survival times)
Number of subjects: 0